Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
PARSIPPANY, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2020 Jefferies Virtual Healthcare Conference on June 3, 2020, at 9:30 AM ET. Interested parties can access the live audio via the company's Events page. A replay will be available for two weeks post-event.
Pacira is known for its non-opioid pain management solutions, including EXPAREL®, a long-acting local analgesic launched in April 2012, and the iovera⁰ system, acquired in April 2019.
PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) will present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on May 20, 2020, at 9:45 AM ET. Interested parties can access a live audio stream on the company's website, with a replay available for two weeks post-event. Pacira is dedicated to non-opioid pain management technologies, including its long-acting local analgesic EXPAREL®, which launched in 2012. The company also acquired the iovera⁰ cryoanalgesia device in April 2019, aiming to enhance pain management and reduce opioid reliance.
Pacira BioSciences (PCRX) reported a 16% revenue increase for Q1 2020, totaling $105.7 million, driven by a 12% rise in EXPAREL sales to $101.3 million. GAAP net income stood at $8.2 million ($0.19/share), a recovery from a net loss of $2.8 million in Q1 2019. Despite early growth, the company has withdrawn full-year guidance due to COVID-19 uncertainties, although it anticipates some mitigation from expense reductions. Cash reserves are strong at $353.6 million, positioning the company for future recovery as elective surgeries resume.
Summary not available.
Summary not available.